Elan Corporation, plc is a biotechnology company, headquartered in Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan was incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. Elan shares trade on the New York and Irish Stock Exchanges.
DUBLIN--(BUSINESS WIRE)--May. 23, 2013--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced the pricing
of the offering of US$850 million aggregate principal amount of 6.250%
Senior Notes due 2021 (the “Notes”) by its wholly-owned subsidiaries,
Elan Finance public limited company and Elan Finance Corp. The Notes
will be issued at par. The offering is expected to close on May 31,
2013, subject to customary closing conditions. The Notes will be ful...
DUBLIN--(BUSINESS WIRE)--May. 23, 2013--
Elan Corporation, plc (NYSE: ELN) (Elan) today announced that its Board
of Directors, after careful review and consideration and with the
assistance of its executive management team as well as outside financial
and legal advisors, has determined that privately held investment firm
Royalty Pharma's revised offer (“Royalty Pharma Offer") announced on
Monday May 20, 2013 to acquire all of Elan's shares for $12.50 per...
Proposed Transactions offer shareholders highly unique investment
and asset proposition
Acquisition of AOP Orphan – a private, orphan disease company
headquartered in Vienna, Austria
Acquires 48% of Newbridge Pharmaceuticals – a private Africa,
Middle East & Turkey (AfMET) company, headquartered in Dubai, UAE
AOP & Newbridge together reach 20%+ of the world’s growing
population ...
DUBLIN--(BUSINESS WIRE)--May. 20, 2013--
Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its
wholly-owned subsidiaries, Elan Finance public limited company (“Elan
Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan
Finance, the “Issuers”), intend to offer, subject to market conditions,
US$800.0 million in aggregate principal amount of Senior Notes due 2021
(the “Notes”). The Notes will be fully and unconditionally guaran...
RSS Feeds | 
E-mail Alerts | 
Contact IR